Best news blogs:
LEUVEN, Belgium, September 1, 2010/PRNewswire-FirstCall/ –
- Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin’s Potential to Transform the Treatment of Retinal Disorders
ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutical companionship focussed on the breakthrough and developing of advanced treatments for eye disease, vascular disease and cancer announces that its sec Phase III visitation evaluating microplasmin for the non-surgical discussion of vitreomacular adherence (VMA) has met its principal termination. Importantly, the run likewise confirmed the overconfident results seen in the low Phase III visitation with microplasmin. The results of the s Phase III visitation (TG-MV-007) were presented for the outset clock at the American Society of Retina Specialists (ASRS) Annual Meeting by Dr. J. Michael Jumper (West Coast Retina and Medical Group and California Pacific Medical Center, California, USA). The run recruited 326 patients at 48 centers in Europe and the U.S.
(more…)